Catalent

Catalent, Inc.
Public company
Traded as NYSE: CTLT
Industry Pharmaceutical
Biotechnology
Predecessor Cardinal Health PTS
Founded 2007
Headquarters Somerset, New Jersey, USA
Number of locations
 33[1]
Key people
 John Chiminski
(President, CEO),
Matthew Walsh
(Executive Vice President, CFO)
Services Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain solutions, regulatory consulting
Revenue US$1.83 billion (2014)[2]
US $374.4 million (2014)[2]
US $142.4 million (2014)[2]
Number of employees
 8,300 (2014)[1]
Website www.catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products. Headquartered in Somerset, New Jersey, Catalent operates 33 locations across five continents,[3] producing more than 70 billion doses annually for nearly 7,000 customer products.[1]

Originally created through a series of acquisitions by Cardinal Health Inc., Catalent became independent in 2007. Catalent promotes its ability to increase customers' speed to market and its participation in nearly half of new drug entities approved by the Food and Drug Administration in the last decade. The company currently holds approximately 1,300 patents and patent applications and continues to expand its offerings through investments in emerging technologies.[1] In its fiscal year 2014 (ending June 30), Catalent’s customers included 83 of the top 100 branded drug marketers, 20 of the top 25 generics marketers, 38 of the top 50 biologics marketers, and 19 of the top 20 consumer health marketers globally. On July 31, 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSE: CTLT).

History

Before 2007

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[4] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[5] In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[6] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[7] In 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[4] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[7] Cardinal Health also acquired International Processing Corporation (Headquarters: Winchester, Kentucky) for its advanced controlled drug release and coating manufacturing expertise.[8]

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[4] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Middleton, Wisconsin).[4] Gala Biotech had established technologies surrounding gene insertion and the production of pharmaceutical proteins, which became GPEx® Technology.[9] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[4] In 2004-2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple other acquisitions.[4]

Formation of Catalent in 2007

In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[10]

After 2007 and Initial Public Offering

In 2011, the Company acquired the molecular optimization platform OptiForm®, from GlaxoSmithKline.[11] In 2012, Catalent acquired Aptuit, a clinical supply solutions company. As part of the deal, Catalent gained three sites in the United States, two sites in the United Kingdom and one in Singapore.[12] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[6] In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a China-based company, and Relthy Laboratories in Brazil.[13] Also in 2013, Catalent created a new business unit, Advanced Delivery Technologies which focuses on innovative and proven drug delivery technologies, optimizing the company’s multiple technologies, cross-platform R&D solutions and global commercial manufacturing network.[14] This is the current structure of Catalent’s business which includes softgel technologies, advanced delivery technologies and development & clinical services business units.

Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[15] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014.[15] The proceeds of the offering went to the redemption of more than $800 million of Catalent’s outstanding debt. “This will allow the company to significantly reduce its interest expense, enable future potential internal and external growth strategies, and to continue our growth-biased investments into new technologies, capabilities, global development and manufacturing facilities and capacity,” a company statement reported.[16]

In September 2016, the company acquired the contract drug development and clinical manufacturing company, which specializes in early stage development and spray drying: Pharmatek Laboratories.[17]

Corporate Governance

Senior Management

Position Name Since
President & Chief Executive Officer and Director John R. Chiminski March 2009[1]
Executive Vice President and Chief Financial Officer Matthew Walsh December 2012[1]
President, Development and Clinical Services Wetteny Joseph August 2009[1]
President, Softgel Technologies Aris Gennadios September 2013[1]
President, Advanced Delivery Technologies Barry Littlejohns July 2013[1]
Senior Vice President, Chief Information Officer Michael Del Priore December 2012[1]
Senior Vice President, Global Sales & Marketing William Downie June 2010[1]
Senior Vice President, Quality, Product Development and Regulatory Affairs Sharon Johnson August 2009[1]
Senior Vice President, Global Operations Stephen Leonard June 2009[1]
Senior Vice President, Human Resources Lance Miyamoto March 2011[1]
Senior Vice President, General Counsel Steven Fasman October 2014[18]

Drug Delivery Technologies

Catalent's brand currently owns and operates the following drug delivery technologies:

Predevelopment Technologies

Oral Drug Delivery Technologies

Sterile Technologies

Biologics

Centers of Excellence

Catalent has designated the following locations as a "Center of Excellence" with the following specializations:

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "The United States Securities and Exchange Commission, (2014). Form 10-K. Washington, D.C.: Catalent Pharma Solutions.". Catalent Pharma Solutions. Retrieved 2014-11-10.
  2. 1 2 3 "Catalent Pharma Solutions, (2014). Catalent Reports Fourth Quarter and Fiscal Year 2014 Results". Catalent Pharma Solutions. Retrieved 2014-11-10.
  3. ↑ "Our Locations". catalent.com. Catalent, Inc. Retrieved 11 Nov 2014.
  4. 1 2 3 4 5 6 "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Retrieved 7 April 2015.
  5. ↑ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
  6. 1 2 "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
  7. 1 2 Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
  8. ↑ "R.P. Scherer to Gain New Drug-Delivery Business With Acquisition of International Processing Corporation". CMO CRO. PR Newswire. 5 December 2000. Retrieved 7 April 2015.
  9. ↑ "Cardinal Health To Enhance Drug Development Services With Acquisition Of Gala Biotech". Cardinal Health, Inc. PR Newswire. 1 Oct 2013. Retrieved 7 April 2015.
  10. ↑ "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
  11. ↑ Ohnesorge, Lauren K. (11 January 2013). "Catalent cements local footprint". Triangle Business Journal. Retrieved 7 April 2015.
  12. ↑ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
  13. ↑ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
  14. ↑ "Catalent Creates New Advanced Delivery Technologies Business Unit". Catalent, Inc. PR Web. 10 July 2013. Retrieved 7 April 2015.
  15. 1 2 "Catalent Issues Initial Public Offering" (8). PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
  16. ↑ "Catalent Issues Initial Public Offering". Catalent.com. Catalent, Inc. Retrieved 7 April 2015.
  17. ↑ http://www.genengnews.com/gen-news-highlights/catalent-to-acquire-pharmatek/81253195/
  18. ↑ "Our Leadership". Catalent. Catalent, Inc. Retrieved 11 Nov 2014.
  19. 1 2 3 "Catalent Announces New Optimized Drug Delivery Technologies at CPhl Worldwide/ICSE". redOrbit. 23 October 2013. Retrieved 7 April 2015.
  20. ↑ "New OptiPact™ Technology Introduced by Catalent". Catalent, Inc. PR Web. 17 September 2014. Retrieved 7 April 2015.
  21. 1 2 "Catalent Expands Its Technology Offerings in Biologics, Acquires Redwood Bioscience Inc. and the SMARTag™ Technology Platform". Catalent Pharma Solutions. MarketWatch. 2 October 2014. Retrieved 7 April 2015.
This article is issued from Wikipedia - version of the 11/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.